Childhood cancers: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• CD19 98
• TP53 8
• PD-1 24
• MYCN 0
• ALK 13
• CD22 30
• BRAF 12
• NF1 12
• ABL1 2
• HER2 25
• PI3K 5
• AKT 1
• CDK4/6 7
• PD-L1 13
• NTRK 10
• NMDA 0
• B7-H3 15
• mTOR 2
• RB1 1
• KMT2A 12
• PSMA 20
• MEK 7
• FLT3 6
• MAPK 5
• CD30 8
• RUNX1 3
• VEGF 5
• IDH 6
• MYC 1
• RET 4
• CD20 12
• ERK 0
• PTEN 2
• CD123 10
• NPM1 9
• EGFR 2
• CTNNB1 2
• FGFR 3
• STAT3 0
• BRCA1 1
• BCL-2 2
• KIT 3
• ROS1 9
• CD33 7
• NRF2 0
• PARP 6
• PPAR 0
• YAP 0
• RAS 1
• CD38 5
• EZH2 0
• JAK 4
• JNK 0
• SNCA 0
• BRCA2 2
• CTLA-4 4
• KRAS 3
• MET 4
• NRAS 0
• VHL 5

24 of 941 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

No running funded project names this disease yet.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Suspended

  Intra-Tumoral Injections of Natural Killer Cells for Recurrent Malignant Pediatric Brain Tumors

  NCT05887882· Sabine Mueller, MD, PhD· Updated 12 Nov 2026

  “Enrollment on hold while reviewing a SAE.”Registry text, quoted unchanged. Source

• Suspended

  Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, GD2-CAR PERSIST Trial

  NCT04539366· National Cancer Institute (NCI)· Updated 12 Nov 2026

  “Other - review of safety data”Registry text, quoted unchanged. Source

• Terminated

  Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

  NCT01552434· M.D. Anderson Cancer Center· Updated 5 Nov 2026

  “\< 75 % participation”Registry text, quoted unchanged. Source

• Terminated

  Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers

  NCT02992964· The Hospital for Sick Children· Updated 5 Nov 2026

  “Withdrawal of drug supply/funding”Registry text, quoted unchanged. Source

• Withdrawn

  xPedite: A Study to Expedite DIPG and DMG Research

  NCT06140719· xCures· Updated 2 Nov 2026

  “Protocol termination”Registry text, quoted unchanged. Source

• Suspended

  PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma

  NCT06639607· Washington University School of Medicine· Updated 30 Oct 2026

  “Drugs/Equipment Unavailable”Registry text, quoted unchanged. Source

• Suspended

  A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

  NCT05691478· National Cancer Institute (NCI)· Updated 27 Oct 2026

  “Other - Extend the observation period for current patients”Registry text, quoted unchanged. Source

• Suspended

  Sodium Thiosulfate Otoprotection During Salvage Cisplatin Therapy

  NCT05756660· Children's Hospital Medical Center, Cincinnati· Updated 22 Oct 2026

  “This study will be closing at CCHMC and may be transferred to a principal investigator at another insitutiton.”Registry text, quoted unchanged. Source

• Terminated

  Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery

  NCT03904862· Pediatric Brain Tumor Consortium· Updated 19 Oct 2026

  “The decision to permanently close PBTC-053 was made following communication from the NCI that the PBTC grant will not be extended beyond March 31, 2026.”Registry text, quoted unchanged. Source

• Terminated

  Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants

  NCT06566092· Iovance Biotherapeutics, Inc.· Updated 16 Oct 2026

  “After reviewing the available safety and efficacy data to date, Iovance has made the decision to conclude all remaining participant visits.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma

  NCT04458922· National Cancer Institute (NCI)· Source

• A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...

  NCT05621291· National Cancer Institute (NCI)· Source

• Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial

  NCT05142241· National Cancer Institute (NCI)· Source

• Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers

  NCT07524530· National Cancer Institute (NCI)· Source

• Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

  NCT07109219· AstraZeneca· Source

• Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

  NCT04284774· National Cancer Institute (NCI)· Source

• Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms

  NCT06303193· National Cancer Institute (NCI)· Source

• Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma

  NCT06831552· Dana-Farber Cancer Institute· Source

• Effect of Therapeutic Storybook Series on Anxiety in Children Undergoing Chemotherapy

  NCT07936318· Asmaa Rashad· Source

• Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

  NCT04320888· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 38
• Organoids 15
• Mendelian Randomization Analysis 12
• CRISPR-Cas Systems 15
• Gene Expression Profiling 125
• Sequence Analysis, RNA 20
• Whole Genome Sequencing 22
• Exome Sequencing 31
• Proteomics 52
• Metabolomics 25
• Mass Spectrometry 13
• Flow Cytometry 87
• Immunohistochemistry 197
• Liquid Biopsy 25
• Circulating Tumor DNA 15
• Xenograft Model Antitumor Assays 134
• Positron-Emission Tomography 52
• Magnetic Resonance Imaging 522
• Machine Learning 69
• Deep Learning 25
• Cohort Studies 328
• Genome-Wide Association Study 22

See which targets of this disease your abstract mentions, and go to the people working on them.